Ryan Hackett, MD
Family Medicine · Elizabethton, TNNPI 1710140249
Payments from drug & device makers
Across 118 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$341
- Novo Nordisk$316
- Amarin Pharma, Inc.$168
- AstraZeneca$142
- AbbVie$119
- Exact Sciences$104
- plus $680 from 21 others
What the payments were for
- Food & beverage$1,864100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $341 |
| Novo Nordisk | 20 | $316 |
| Amarin Pharma, Inc. | 10 | $168 |
| AstraZeneca | 9 | $142 |
| AbbVie(2 entities) | 8 | $119 |
| Exact Sciences | 6 | $104 |
| Pfizer | 7 | $92 |
| Kowa Pharmaceuticals America, Inc. | 4 | $74 |
| Lilly USA, LLC | 4 | $60 |
| Medtronic | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Novartis | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 2 | $25 |
| GSK | 2 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Corium, LLC | 1 | $19 |
| Bayer | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
How this compares
$1,870 in reported general payments places this provider in the 65th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $144,888 |
| OzempicSemaglutide | 84 | $114,198 |
| MounjaroTirzepatide | 56 | $66,390 |
| XareltoRivaroxaban | 72 | $63,452 |
| TrulicityDulaglutide | 39 | $46,128 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $45,975 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $37,463 |
| FarxigaDapagliflozin Propanediol | 32 | $30,573 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $29,987 |
| JardianceEmpagliflozin | 17 | $29,638 |
| LinzessLinaclotide | 38 | $26,431 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $25,099 |
| JanuviaSitagliptin Phosphate | 35 | $24,692 |
| Spiriva RespimatTiotropium Bromide | 25 | $24,190 |
| BrilintaTicagrelor | 31 | $18,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $144,888148 claims |
| Novo NordiskOzempic, Tresiba | $316 | $117,70695 claims |
| Lilly USA, LLCMounjaro, Trulicity | $60 | $112,51895 claims |
| Johnson & JohnsonXarelto | $341 | $63,45272 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $142 | $56,30684 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $33 | $53,82842 claims |
| GSKTrelegy Ellipta | $24 | $29,98745 claims |
| AbbVieLinzess | $119 | $26,43138 claims |
| NovartisEntresto | $35 | $13,26019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Elizabethton
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.